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Peptide hormone fibroblast growth factor-21 (FGF21) has insulin-mimetic properties. Dutchak et al.
now suggest that FGF21 also acts in an autocrine fashion in adipocytes and is required to mediate
effects of the PPARg agonist class of antidiabetic drugs. Does this new property improve FGF21’s
fledgling clinical prospects or endorse a clinical resuscitation of PPARg agonists?The search for peptides with insulin-like
metabolic properties harks back to the
unmet need for insulin sensitizers to treat
diabetes and obesity. Among fibroblast
growth factors (FGFs), FGF21 is conspic-
uousby its failure tobindheparin, a feature
that effectively turns it from paracrine
growth factor into bona fide hormone. A
study in this issue of Cell by Dutchak
et al. (2012) shows that FGF21 sensitizes
adipocytes to the actions of peroxisome
proliferator-activated receptor g (PPARg)
and is required to achieve the full effects
of PPARg ligands of the thiazolidinedioneFigure 1. Representative Diagram of the Proposed Mechanism of
FGF21 Action
Liver is the primary source of circulating FGF21, and hepatic synthesis is
driven by PPARa activation. In addition, adipocytes are a secondary source of
FGF21. But unlike hepatocytes, adipocytes make FGF21 in response to
PPARg agonists (TZDs) or feeding. Plasma levels of FGF21 don’t change
significantly following PPARg activation, indicating that adipocyte-derived
FGF21 acts locally. Its main role appears to be to potentiate the effects of
PPARg activation on adipocyte differentiation and gene expression. None-
theless, systemic actions of PPARg agonists are also impaired by the loss of
FGF21.(TZD) class of antidiabetic
drugs. TZDs function as
PPARg agonists and until
recently were the second-
most prescribed group of
oral insulin sensitizers. In an
unexpected twist, Dutchak
et al. link the mechanism of
FGF21 sensitization to PPARg
sumoylation, raising the ques-
tion of whether the latter—
or germane posttranslational
modifications—can be lever-
aged to more effectively
employ TZDs for the treat-
ment of metabolic diseases.
Circulating FGF21 is
hepatic in origin and shows
limited circadian variations,
except under prolonged fast-
ing (Badman et al., 2007).
In humans, plasma FGF21
levels vary considerably
among individuals, are ele-
vated in insulin-resistant dia-
betics, and are decreased by
administration of TZDs. How-
ever, pharmacological admin-
istration of FGF21 results inmultiple metabolic benefits: it lowers gly-
cemia by promoting peripheral utilization
and decreasing hepatic production of
glucose; it lowers triglycerides and total
as well as LDL cholesterol; it decreases
liver fat and body weight; and it promotes
b cell growth (Wente et al., 2006). It should
be pointed out that the pharmacology and
the physiology of FGF21 are somewhat
discordant, and that not all pharmacolog-
ical effects can be ascribed to the endog-
enous peptide.
The broad-based metabolic effects of
FGF21 on glucose and lipid metabolismCell 148likely reflect its dual regulation by PPARa
in liver (Inagaki et al., 2007) and by PPARg
in adipocytes (Muise et al., 2008; Wang
et al., 2008). The study by Dutchak et al.
provides insight into this dual regulation
by showing that liver- but not adipocyte-
derived FGF21 is stimulated by PPARa
ligands. Conversely, TZDs—or feeding—
promote FGF21 production in adipocytes
but not in liver, effectively establishing
a closed loop in which adipocyte-derived
FGF21 acts in an autocrine fashion to
amplify the effects of PPARg activation
without changes to systemic FGF21, February 3levels (Figure 1). The regula-
tion of FGF21 in the fed state
raises an interesting physio-
logical question, as FGF21
has thus far been considered
a ‘‘fasting’’ or ‘‘starvation’’
signal. Why would the same
hormone be induced by fast-
ing in one organ and by
feeding in another? One
potential explanation is that
the autocrine function of
FGF21 in adipocytes has
evolved to buffer this cell
type against drops in liver-
derived FGF21, suggesting
an ‘‘adipostat’’-like role for
FGF21. For example, as pro-
posed by the authors, FGF21
might be involved in regu-
lating futile energy cycling by
way of the glycerol/fatty acid
cycle (Reshef et al., 2003).
A striking aspect of
Dutchak et al. is the impaired
response to TZDs in mice
lacking FGF21. However, we
should focus on the fact that
TZDs retain some therapeutic, 2012 ª2012 Elsevier Inc. 397
properties in FGF21 knockout mice, such
as the ability to lower plasma insulin and
triglyceride levels, as well as hepatic
fat—even as the detrimental effects of
these drugs on body weight and fluid
balance are lost. This finding suggests
that the detrimental effects require an
intact TZD-FGF21 autocrine loop (Fig-
ure 1). This cannot be easily reconciled
with a strictly autocrine mechanism, in
that the effects of TZDs on fluid balance
are thought to arise as a consequence of
PPARg activation in tissues other than
adipose, but the boundaries between
cell-autonomous and -nonautonomous
functions of PPARg are necessarily
blurred. On balance, the therapeutic pro-
file of TZDs in FGF21 knockout mice
suggests that the key to avoiding the
dreaded side effects of these compounds
is to settle for lower metabolic benefits.
A more enigmatic aspect of Dutchak
et al. is the proposed association of
PPARg sumoylation with TZD action.
In macrophages, TZDs induce PPARg
Lys395 sumoylation to repress inflamma-
tory genes, and this modification has
been linked to the beneficial anti-inflam-
matory actions of TZDs (Pascual et al.,
2005). Dutchak et al. show that in adipose
tissue, TZDs have the opposite effect to
decrease PPARg Lys107 sumoylation,
and that this effect is lost in FGF21
knockout mice. The mechanism of the
rise of PPARg Lys107 sumoylation in
FGF21-deficient fat cells and the ap-
parent paradox of the differential effects
of TZDs on PPARg sumoylation on
different sites and different cell types398 Cell 148, February 3, 2012 ª2012 Elseviedeserve further investigation. Among
the questions that will have to be ad-
dressed are whether these modifications
are tissue-specific, and whether they
are interdependent. In addition, much
remains to be discovered with regard to
the integration of PPARg sumoylation on
different sites with other posttranslational
modifications, especially phosphorylation
(Choi et al., 2010).
But the elephant in the room is whether
any answer to these questions can
change the pharmaceutical industry’s
gun-shy stance in this area, what with
growing regulatory concerns and as-
sorted liabilities left in the wake of current
TZDs. Ideally, one would want to design
a PPARg ligand endowed with TZDs’
metabolic effects and shorn of its cardio-
vascular, oncogenic, and bone loss
comorbidities. The question raised by
Dutchak et al. in this regard is whether
acting on PPARg’s posttranslational
modification might provide an alternative
approach to reach that goal.
Finally, do the present findings affect
the prospects of clinical development of
FGF21 and related biologicals? Probably
not, for several reasons: first, the broad
metabolic benefits of FGF21 make it
uniquely attractive; second, none of the
reported liabilities of TZDs have thus
far been reported in the FGF21 clinical
trial literature; and third, the effects of
endogenous FGF21 to mediate the
actions of TZDs don’t necessarily portend
its ability to do so when administered
pharmacologically, as there appears to
be a dichotomy between the effects ofr Inc.the endogenous peptide and pharmaco-
logical administration of the recombinant
peptide. Even so, further studies of this
fascinating class of hormones are likely
to reveal aspects of integrated meta-
bolism that can be used to develop new
treatments for diabetes and obesity.
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